ArticleArchives of pharmacal research2025
Human YKL-40 antibody alleviates atopic dermatitis-like skin inflammation by inhibiting exosome secretion via the JAK3/STAT6 pathway.
Article in Archives of pharmacal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- eHsp90α enhances breast cancer cell invasion by activating the LRP1-EGFR/AKT-twist/snail signaling axis in cancer-associated fibroblasts.Archives of pharmacal research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Atopic dermatitis (AD) is an inflammatory skin disease that produces a variety of inflammatory cytokines and chemokines. Chitinase-3-like protein 1 (CHI3L1, YKL-40) significantly contributes to AD-associated inflammatory response and is highly expressed in patients with AD. Therefore, this study elucidated the effects and potential mechanisms of human YKL-40 antibody on AD-affected skin. The anti-AD like inflammatory effects and inhibition of exosome release effectors of human YKL-40 antibody were evaluated. Since exosomes have been closely related to AD inflammation and cytokine production, we detected exosome release in in vitro reconstituted human skin (RHS) models and HaCaT cells. Cytokine expression was analyzed using enzyme-linked immunosorbent assay (ELISA) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, related signaling pathways were evaluated using Western blotting and immunofluorescence staining. Human YKL-40 antibody significantly inhibited epidermal hyperplasia commonly induced by AD in the RHS model. In addition, this antibody effectively reduced the secretion of AD-associated inflammatory cytokines. Furthermore, it inhibited the expression of CD63, a marker for exosomes, and the phosphorylation of JAK3/STAT6, which are primarily involved in signaling pathways for AD and exosome release. This study provides strong evidence supporting the potential therapeutic efficacy of human YKL-40 antibody in the treatment of AD. It offers a new therapeutic approach for patients with incurable inflammatory skin diseases.
Indexed as
Identifiers
40924285What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.